News & Clinical Trials

Curated updates on clinical trials, peer-reviewed papers, and reputable coverage related to compounds discussed on this site for cancer and other serious diseases. This page is informational only — not medical advice, diagnosis, or a treatment recommendation. Always consult a qualified healthcare professional. No entry implies proven efficacy.

Browse all

118 of 118 entries, newest first
DateCompoundTitle TypePhaseStatus
Ivermectin Artif Cells Nanomed Biotechnol: inhalable ivermectin nanoparticles worked somewhat better than plain ivermectin against lung cancer cells (lab only)
Summary

Lab study in cells (Kassaee et al., Queensland University of Technology): researchers packed ivermectin into lipid-polymer hybrid nanoparticles designed to be inhaled, and tested them on A549 and H460 non-small cell lung cancer cell lines. The nanoparticle form lowered the dose needed to kill half the cells (IC50) by about 20% versus free ivermectin, cut colony formation by more than half, and slowed cell growth and migration more than free ivermectin. Empty nanoparticles did not harm the cancer cells, and the formulations showed no considerable toxicity to normal human bronchial cells in the dish. In lab cells only; the inhaled form was not tested in animals or people, and the authors say animal studies are still needed.

Lab study (cancer cell lines, inhalable formulation) · 2026
Lab study Preclinical
Mebendazole Absorption study — Pharmaceutics: urea-based mebendazole prodrugs raised blood levels in mice (no cancer outcome tested)
Summary

Absorption study — in mice, no cancer outcome tested (Färnegårdh et al.): researchers made urea-based prodrugs of mebendazole (MBZ) meant to absorb better through the gut and then release parent MBZ in the body. In mouse oral pharmacokinetic studies, a lead prodrug (2i) gave about a 10-fold higher peak MBZ blood level (Cmax) and about a 2-fold higher overall MBZ exposure (AUC) versus an equimolar dose of MBZ; the authors note the prodrug was given as a solution and MBZ as a suspension. Lab chemistry plus mouse blood-level work only; no tumor or cancer efficacy was tested; not tested in people.

Absorption study (mouse PK, no cancer outcome) · 2026
Animal study Preclinical
HCQ J Mater Chem B: a hydrogel carrying hydroxychloroquine and a chemo drug cut tumor regrowth after surgery in animal tests
Summary

Preclinical study (Yi et al.): researchers made a gel that is injected into the space left after a tumor is removed. It slowly releases hydroxychloroquine (HCQ), used here to break down neutrophil extracellular traps (immune-cell debris that can help leftover cancer cells regrow and spread), together with a polymer that delivers the chemo drug camptothecin to cancer cell mitochondria. In the authors' lab and animal tumor models, the combined gel reduced local tumor regrowth and spread to the lungs. HCQ was one part of a combination, so its effect alone is unclear. Not tested in people.

Animal study (tumor models) · 2026
Animal study Preclinical
Methylene Blue Cell Death Dis: ATC-37 (made from a methylene blue relative, not methylene blue itself) slowed mutant-p53 pancreatic tumors in mice
Summary

Preclinical study (Lee, Pham et al.): researchers built ATC-37, an AUTOTAC drug that links a methylene blue–derived amyloid-binding piece (not methylene blue itself) to an autophagy-targeting ligand that activates p62/SQSTM1, aiming it at aggregated mutant p53. In lab tests and a PANC-1 pancreatic cancer mouse xenograft model, ATC-37 reduced tumor growth and mutant-p53 aggregates and also made the cancer cells more sensitive to radiation. Animal/preclinical only; ATC-37 is a new engineered compound related to methylene blue, not methylene blue taken as a drug; not tested in people.

Animal study (pancreatic xenograft) · methylene blue–derived compound · 2026
Animal study Preclinical
HCQ J Biochem Mol Toxicol: hydroxychloroquine boosted the diabetes drug empagliflozin against lung cancer cells in the lab
Summary

Preclinical study (El-Feky et al.): researchers tested empagliflozin, a diabetes drug (SGLT2 inhibitor), alone and with hydroxychloroquine (HCQ), which blocks the cell recycling process called autophagy, in two human lung cancer cell lines (A549 and HOP-92), alongside computer target-prediction and docking work. Empagliflozin reduced cancer cell survival and increased cell death, and adding HCQ lowered the dose needed and worked synergistically in these cells. Lab cells only; not tested in animals or people.

Lab study (cell lines) · 2026
Lab study Preclinical
Fenbendazole Drug Chem Toxicol: fenbendazole hit ovarian cancer cells harder than normal ovarian cells in the lab
Summary

Preclinical lab study from Turkey: researchers exposed two ovarian cancer cell lines (OVCAR8 and A2780) and a non-cancerous ovarian cell line (IOSE-80) to fenbendazole. Fenbendazole lowered cancer cell survival depending on dose and time, was most potent in A2780, and did not reach a 50% kill level in the non-cancerous cells within the doses tested. In the cancer cells it stalled cell division (G2/M arrest) and raised markers of DNA damage and cell death. A computer docking check hinted at a tubulin-related mechanism, but the authors say it is not proof. Lab cells only; not tested in animals or people.

Preclinical (ovarian cancer and nonmalignant cell lines) · 2026
Lab study Preclinical
IvermectinFenbendazole Computer modeling (not peer-reviewed) — Zenodo: modeling study finds ivermectin and fenbendazole blood levels at safe oral doses fall far short of lab cancer-killing concentrations across seven cancers
Summary

Self-published computer-modeling study (Rai and Jain, IIT Roorkee; posted to Zenodo Oct 29, 2026). Not peer-reviewed, and not tested in cells, animals or people: all results come from computer models. The authors ran a computational pharmacology pipeline (network pharmacology, molecular docking, pathway modeling) plus a pharmacokinetic check comparing published human peak blood levels with lab killing concentrations, across glioblastoma, AML, triple-negative breast, colorectal, non-small-cell lung, pancreatic cancer and melanoma. They report that lab killing concentrations (IC50: ivermectin 3–15 μM, fenbendazole 0.8–3.0 μM) were up to about 30 times higher than the peak total blood levels reachable at documented safety limits; after correcting for protein binding, the free-drug shortfall ranged from 12.3× (fenbendazole, lung cancer) to 439.6× (ivermectin, colorectal cancer). Their plausibility score rated none of the seven cancers "promising", five "worth further preclinical study" (triple-negative breast, lung, colorectal, melanoma, AML; 42–51 of 100) and two "implausible at safe doses" (pancreatic, glioblastoma; 33). The strongest modeled binding signals (ivermectin–PAK1, fenbendazole–β-tubulin) matched known mechanisms, and a pathway model predicted 87.9% cell death when chemotherapy was combined with low-dose ivermectin and fenbendazole. The authors conclude the anticancer biology is real but oral doses cannot match lab killing levels without exceeding liver and nerve toxicity limits, and suggest IV or liposomal reformulation or trials using the drugs as add-ons to standard chemotherapy.

Computer modeling (PBPK + network pharmacology) · not peer-reviewed · 2026
Other Preclinical
HCQ Cell Commun Signal: hydroxychloroquine helped the PARP drug niraparib against resistant ovarian cancer in lab cells and mice
Summary

Preclinical study: researchers ran a genome-wide CRISPR screen in ovarian cancer cell lines and mouse xenografts treated with the PARP inhibitor niraparib, and found that the gene UGCG drives resistance by boosting sphingolipid metabolism and autophagy (a cell recycling process tumors can use to survive treatment). Blocking UGCG with eliglustat restored niraparib sensitivity, and adding metformin or hydroxychloroquine to block autophagy further reduced autophagy and tumor growth in lab cells and in mice. Patient-derived organoids were also used to check the findings. Lab and animal work only; the HCQ combination has not been tested in people with ovarian cancer.

Preclinical (cell lines, mouse xenografts, organoids) · 2026
Animal study Preclinical
Ivermectin Side-effect care — Memorial Sloan Kettering Phase 2 trial: oral ivermectin to prevent skin rash from the pancreatic cancer drug daraxonrasib (NCT07895498) — recruiting
Summary

Supportive-care trial (Memorial Sloan Kettering Cancer Center, protocol 26-384; recruiting since Oct 16, 2026, target n=122): a randomized, open-label Phase 2 study in people with metastatic pancreatic cancer taking the RAS-inhibitor cancer drug daraxonrasib. Participants are randomly assigned to standard skin-rash prevention alone (oral minocycline 100 mg twice daily, morning facial hypochlorous acid solution, topical steroid creams—hydrocortisone 2.5% on the face, triamcinolone 0.1% on the trunk, clobetasol 0.05% on the scalp—plus daily SPF 30+ sunscreen) or the same standard care plus oral ivermectin 200 mcg/kg once a week. The main outcome is pustular skin rash severity at day 56 (CTCAE v6.0 grades 0–3), along with quality-of-life questionnaires. Labeled as side-effect care: this trial tests ivermectin to prevent a cancer-treatment side effect (skin toxicity from daraxonrasib), not as an anticancer treatment against the pancreatic tumor itself. Trial registry listing only; no results posted yet.

Phase II · target n=122 · randomized, open-label · side-effect care · recruiting
Clinical trial Phase 2 Recruiting
HCQ ClinicalTrials.gov results: sorafenib plus hydroxychloroquine in advanced liver cancer (NCT03037437)
Summary

Registry results posted Oct 21, 2026 for a small Phase 2, non-randomized trial at UT Health San Antonio (2017 to 2025). 32 people with advanced hepatocellular carcinoma (liver cancer) who had not had prior systemic treatment started sorafenib, with hydroxychloroquine 400 mg daily added from day 15. Their median time to tumor progression was 8 months (95% CI 4 to 19 months). Only 25 finished the first cycle and 2 completed a full year of treatment. A second group of 5 patients who had already progressed on sorafenib had HCQ added, but none were evaluable. There was no sorafenib-only comparison group, so these results cannot show whether HCQ added any benefit. Results are posted on the registry only; no journal paper yet.

Phase II · n=37 · single-arm, no control · registry results · 2026
Clinical trial Phase 2 Completed
Ivermectin BMC Pharmacol Toxicol: ivermectin weakened cisplatin against oral cancer cells in the lab
Summary

Lab study (Tantawy et al., British University in Egypt): in HN9 oral squamous cell carcinoma cells, adding ivermectin to the chemotherapy drug cisplatin killed fewer cancer cells than cisplatin alone. The combination reduced cisplatin's S-phase cell-cycle arrest and lowered pro-apoptotic markers (BAX, caspase-3); the authors suggest ivermectin's antioxidant and anti-inflammatory effects may interfere with cisplatin. A negative (antagonistic) result in one lab cell line only; not tested in animals or people.

Lab study (cell lines) · 2026 · negative
Lab study Preclinical
Mebendazole PLoS One: Mebendazole restores gefitinib activity in gefitinib-resistant lung cancer models
Summary

Preclinical study (El-Tanani et al.): in gefitinib-resistant EGFR-mutant NSCLC cells (HCC827 GR5), gefitinib alone barely reduced viability (92.7%), while mebendazole 0.1 µM + gefitinib 1 µM cut viability to 37.7%, with increased DNA damage and γ-H2AX replication-stress signaling. In a mouse model the combination slowed tumor growth (doubling time 6.2 to 25 days) without obvious systemic toxicity. Cell and animal data only; not tested in patients.

In vitro + xenograft · 2026
Animal study Preclinical
HCQ Arabian J Chem: hydroxychloroquine plus resveratrol nanoparticles kill liver cancer cells in the lab
Summary

Preclinical study (Mohammed et al.): researchers packed hydroxychloroquine and resveratrol together into coated nanoparticles. In HepG2 liver cancer cells the nanoparticles were more toxic than either free drug, triggered apoptosis and affected autophagy, and were less toxic to normal skin cells. A 30-day oral study in mice looked only at safety and found no deaths and mild liver changes. No tumor-shrinkage testing in animals or patients yet.

In vitro + mouse safety · 2026
Lab study Preclinical
IvermectinMebendazole RETRACTED: Ivermectin + mebendazole observational cohort (Anticancer Research / Hulscher et al.)
Summary

The June 2026 Anticancer Research self-reported telemedicine cohort of ivermectin plus mebendazole (Hulscher et al.; Anticancer Res 2026 Jun;46(6):3243-3255; original PMID 42203321; DOI 10.21873/anticanres.18194; n=197 enrolled / 122 follow-up) claimed a high rate of clinical benefit. Fully retracted October 2026 (Anticancer Res 2026 Oct;46(10):5877; PMID 42823188; DOI 10.21873/anticanres.18425). Timeline: Expression of Concern 9 Jun 2026 (PMID 42300708), update Sep 2026 (PMID 42703869), full retraction Oct 2026. Grounds were methodological and analytical problems after post-publication review, independent expert assessment, and the authors' appeal — not fabrication. Do not cite the unretracted framing as supporting evidence. Retraction: https://pubmed.ncbi.nlm.nih.gov/42823188/. Evidence level: retraction notice.

Retraction notice
Retraction
Fenbendazole Registry note: no dedicated fenbendazole cancer interventional trials on ClinicalTrials.gov
Summary

As of this curation scan, ClinicalTrials.gov queries for fenbendazole return parasitology/oxfendazole and unrelated studies — not registered human cancer treatment trials of fenbendazole. Evidence level: registry observation; human oncology evidence remains preclinical/case-level.

Registry scan 2026
Other
Ivermectin Toxics: short ivermectin course eased ovary damage from the immunotherapy drug atezolizumab in rats
Summary

Animal study (Wistar rats, six per group, no tumors): rats given the checkpoint inhibitor atezolizumab showed oxidative stress, inflammation and ovary damage. Ivermectin 2 mg/kg by mouth for 3 days beforehand lessened these changes and preserved the fertility hormone AMH, but a 6-day course did not help much. This tests side-effect protection, not cancer treatment; small rat study only; not tested in people.

Animal study (rats, supportive care) · 2026
Animal study Preclinical
HCQ Future J Pharm Sci (2026): meta-analysis finds adding HCQ to chemotherapy did not improve tumor response
Summary

Systematic review and meta-analysis (Al-Talqani et al.) of 7 studies, 383 adults with cancer, comparing chemotherapy plus hydroxychloroquine against chemotherapy alone or placebo. Adding HCQ did not significantly improve objective response (OR 0.67; 95% CI 0.30–1.46), complete or partial response, or stable disease. Side effects such as headache and nausea were similar between groups. The authors call for larger randomized trials. Evidence level: meta-analysis of small studies; negative result.

Meta-analysis · 7 studies, n=383 · 2026
Review
Methylene Blue Angew Chem: DNA nanorobot carrying methylene blue for light-activated therapy shrank tumors in mice
Summary

Preclinical study (Fan et al.): researchers built a DNA-based nanorobot carrying methylene blue as a light-activated (photodynamic) drug plus platinum particles that make oxygen inside tumors. The oxygen bubbles helped it push deeper into tumor tissue and eased low oxygen, which made the light treatment work better; the authors report 85% tumor regression in mice. An engineered nanodevice with light treatment, not methylene blue taken by mouth; mice only; not tested in people.

Lab + mouse study (photodynamic) · 2026
Animal study Preclinical
Methylene Blue Chem Sci: adding thymoquinone kept methylene blue active for light-activated (photodynamic) tumor cell killing in the lab
Summary

Lab study (Xiong et al.): methylene blue used in photodynamic therapy (light-activated treatment) tends to be switched off by reducing chemicals inside the body. The researchers added electron-accepting "protector" compounds such as thymoquinone, which kept methylene blue active and raised its light-triggered reactive oxygen output about 4.9-fold under those conditions. In lab tests the combination killed tumor cells about 1.8 times better than methylene blue alone. Chemistry and lab cells only; not tested in animals or people.

Lab study (cell lines) · 2026
Lab study Preclinical
HCQ Biomaterials: HCQ-loaded nanoparticle boosted radiation and immunotherapy against liver cancer in mice
Summary

Preclinical study (Fang et al.): a nanoparticle loaded with hydroxychloroquine was designed to jam the autophagy recycling system in liver cancer cells. It increased immune-alarm (cGAS-STING) signaling and cell damage, and with radiotherapy it improved tumor control in mouse models, including distant tumors, with a further benefit when a checkpoint inhibitor was added. A complex engineered nanoparticle, not plain HCQ; cells and mice only; not tested in people.

Lab + mouse study (nanoparticle) · 2026
Animal study Preclinical
Mebendazole Nature Communications: mebendazole blocks the OCTN1 transporter and slows cervical and lung cancer cell growth
Summary

Preclinical study (Xu et al.): researchers solved cryo-EM structures of the human OCTN1 transporter, which has been linked to cancer cell growth and invasion. Structure-based virtual screening then identified mebendazole as a potent OCTN1 inhibitor, and mebendazole suppressed the proliferation of cervical and lung cancer cells. Structural and cell-culture data only; not tested in animals or patients in this report.

Structural + in vitro · 2026
Lab study Preclinical
Ivermectin Cells: ivermectin blocks stress-granule recovery and Hsp70 production in neuroblastoma cells
Summary

Preclinical study (Chu et al., McGill University): in human neuroblastoma cells, ivermectin delayed the clearance of stress granules and reduced new production of the protective chaperone Hsp70, by blocking its translation rather than its gene expression. The Hsp70 effect was not seen in cervical carcinoma cells. Cell-culture mechanism data only; no animal or patient results.

In vitro · 2026
Lab study Preclinical
IvermectinFenbendazole Front Oncol case report: melanoma briefly responded during self-directed ivermectin and fenbendazole, then progressed
Summary

Case report (Cheng and Araujo, University of Florida): a 74-year-old man with metastatic melanoma declined standard therapy and took ivermectin and fenbendazole on his own. His tumors and ctDNA (Signatera, 2.04 to 0.18 MTM/mL) initially fell, then both worsened (ctDNA 0.93 MTM/mL, growing axillary node). Because the tumor was extremely high-mutation and immunogenic, the authors note spontaneous immune regression is equally plausible as a drug effect, note there is no clinical evidence of efficacy, and urge safety counseling. Single patient; cannot show cause and effect.

Case report · 2026
Case report
HCQ Pilot HCQ for aromatase-inhibitor musculoskeletal symptoms (AIMSS) (NCT07825454) [Pending]
Summary

Indiana University Phase II pilot of hydroxychloroquine for joint pain from aromatase-inhibitor–associated musculoskeletal symptoms in breast cancer patients (n≈35). Supportive-care focus. Evidence level: planned pilot; no results yet.

Phase II · not yet recruiting · supportive care
Clinical trial Phase 2 Not yet recruiting
HCQ Phase I: oral decitabine/cedazuridine + venetoclax + HCQ in AML (NCT07814339) [Pending]
Summary

Rutgers Phase I dose-finding study of hydroxychloroquine added to oral decitabine/cedazuridine and venetoclax in acute myeloid leukemia (n≈18). Evidence level: planned early Phase I; no results yet.

Phase I · not yet recruiting
Clinical trial Phase 1 Not yet recruiting
Ivermectin ICONIC: ivermectin + immune checkpoint inhibition in solid tumors (NCT07487805) [Pending]
Summary

University of Florida Phase II randomized study comparing intermediate- vs high-dose ivermectin with standard immune checkpoint inhibitors in adults with solid tumors. Evidence level: planned interventional trial; no results yet.

Phase II · not yet recruiting
Clinical trial Phase 2 Not yet recruiting
Mebendazole Cell Physiol Biochem: mebendazole plus flutamide inhibits prostate cancer cells more than either drug alone
Summary

Preclinical study (Fattahi et al., Tehran University of Medical Sciences): in three prostate cancer cell lines (LNCaP, DU145, PC3), combining mebendazole with the anti-androgen flutamide reduced cell viability, colony formation and migration more than either drug alone, and increased apoptosis. Mebendazole IC50 was about 55 µM. Authors suggest the combination could allow lower flutamide doses. Cell-culture data only; not tested in animals or patients.

In vitro · 2026
Lab study Preclinical
HCQ ACS Appl Polym Mater: polymer carrying gemcitabine plus hydroxychloroquine tested on pancreatic cancer cells
Summary

Lab chemistry study (Degirmenci et al.): researchers built polymers that carry both the chemotherapy drug gemcitabine and hydroxychloroquine and tested different chemical links for releasing each drug. The best version released both drugs well, was more toxic to pancreatic cancer cells and was taken up by BxPC-3 cells and 3D tumor spheroids. Lab cells only; no animal or human data.

Lab study (drug delivery, cell lines) · 2026
Lab study Preclinical
Mebendazole Cell Reports Medicine (2026): ketogenic diet enhances mebendazole + devimistat in juvenile HGG models
Summary

Mouse study reporting that nutritional ketosis may enhance therapeutic effects of mebendazole combined with CPI-613 (devimistat) in juvenile high-grade glioma models. Evidence level: preclinical animal only.

Mouse HGG · 2026
Animal study Preclinical
Mebendazole Oncology Research (2026): mebendazole antiproliferative/antimigratory effects in paediatric LGG models
Summary

Preclinical evaluation of mebendazole in paediatric low-grade glioma models showing antiproliferative and antimigratory effects. Evidence level: preclinical — complements existing pediatric glioma trial listings.

In vitro models · 2026
Lab study Preclinical
Mebendazole Br J Clin Pharmacol (2026): systematic review of mebendazole repurposing for brain tumours
Summary

Systematic review synthesizing preclinical and clinical evidence for mebendazole in primary brain tumours, including CNS penetrance and multimodal anticancer mechanisms. Evidence level: systematic review — summarizes, does not replace, controlled trials.

Systematic review · 2026
Review
IvermectinMebendazole J Biol Chem abstract: ivermectin, mebendazole and albendazole tested together in colorectal cancer cells
Summary

Meeting abstract (Reynolds and Fly, J Biol Chem vol. 302 suppl., Abstract 4275): reports lab tests of the antiparasitic drugs ivermectin, mebendazole and albendazole in colorectal cancer cells, with the authors describing selective and synergistic anticancer activity. This is a short conference abstract, not a full peer-reviewed paper, and results are in lab cells only; not tested in people.

Conference abstract · lab (cell lines) · 2026
Lab study Preclinical
Ivermectin J Adv Biotechnol Exp Ther: vitamin C plus ivermectin in cervical cancer cells showed mostly additive, weakly synergistic effects
Summary

Exploratory lab study (Onsoti et al., Kenya): in HeLa cervical cancer cells, ivermectin (IC50 about 9.65 µM) and ascorbic acid (vitamin C, IC50 about 4.58 mM) each slowed cell growth. Combined, the effect was additive near those doses and synergistic only at higher concentrations; the authors call the synergy weak. Gene tests showed TP53 up and STAT3, BCL2, HIF1α and TNF down. Lab cells only; not tested in people.

Lab study (cell line) · weak synergy · 2026
Lab study Preclinical
Ivermectin PLoS One (2026): ivermectin inhibits ER, HER2, and TGF-β pathways in endocrine-resistant breast cancer cells
Summary

Cell-line study reporting that ivermectin modulates ER, HER2, and TGF-β signaling in ER-positive and endocrine-resistant breast cancer models. Evidence level: preclinical in vitro only.

In vitro · 2026
Lab study Preclinical
Methylene Blue Acta Pharm Sin B: methylene blue light-activated prodrug with an immune booster slowed melanoma in mice
Summary

Preclinical study (Zhi et al.): researchers chemically linked methylene blue, used as a light-activated (photodynamic) drug, to a new immune-stimulating TLR2 agonist, packed it into nanoparticles coated with melanoma cell membranes, and designed it to release inside tumors. With light treatment it killed tumor cells, boosted immune activity against the tumor and suppressed melanoma growth in mice, and the authors report protection against distant tumor growth. An engineered nanoparticle with light treatment, not methylene blue taken by mouth; cells and mice only; not tested in people.

Lab + mouse study (photodynamic) · 2026
Animal study Preclinical
Ivermectin J Gastrointest Oncol (2026): ivermectin suppresses gastric cancer cell lines and organoids
Summary

In vitro study reporting tumor-growth suppression by ivermectin in gastric cancer cell lines and patient-derived organoids. Evidence level: preclinical cell/organoid work — not human clinical efficacy.

In vitro + organoids · 2026
Lab study Preclinical
HCQ Side-effect care — EJC Skin Cancer: retrospective study of hydroxychloroquine alongside steroids for immunotherapy-induced lung inflammation in melanoma
Summary

Retrospective supportive-care cohort study (Eicher et al., University Hospital Zurich, Nov 2014 to Jan 2025): among 46 adults with metastatic melanoma who developed moderate-to-severe lung inflammation (CTCAE grade ≥2 immune-related pneumonitis) from immune checkpoint inhibitors, 10 received hydroxychloroquine (HCQ) alongside steroids and 36 did not. Patients given HCQ had a higher total steroid dose (median 4,514 mg vs. 1,627 mg) and longer steroid treatment (131 vs. 85 days; difference not statistically significant), likely reflecting use in harder-to-treat cases. After HCQ was started, average daily steroid dose dropped from 88.9 mg/day to 23.3 mg/day, similar to the non-HCQ group (23.1 mg/day), and two HCQ-treated patients had their pneumonitis resolve without steroids or other immune-suppressing drugs. HCQ was well tolerated (mild side effects in 1 of 10). The authors note that the small sample, sicker patients being chosen for HCQ (indication bias), and confounding prevent firm conclusions and call for a randomized trial. Labeled as side-effect care: this study evaluates HCQ for an immunotherapy side effect, not as an anticancer treatment against melanoma itself.

Retrospective cohort · n=46 (10 HCQ, 36 control) · side-effect care · 2026
Observational
HCQ BMC Pharmacol Toxicol (2026): sorafenib + HCQ synergy in KRAS-mutant breast cancer models
Summary

Computational-experimental study reporting synergistic responses to sorafenib plus hydroxychloroquine in KRAS-mutant breast cancer models. Evidence level: preclinical — not a clinical trial result.

In vitro · 2026
Lab study Preclinical
HCQ HCQ + TAE for hepatocellular carcinoma (NCT05842174 / TAQE) — recruiting
Summary

VA-sponsored Phase I/II randomized study (estimated n≈93; start 2026-04-01) of intra-arterial hydroxychloroquine in lipiodol with transarterial embolization (TAE), then oral HCQ maintenance, versus lipiodol/TAE plus oral placebo, for intermediate-stage unresectable HCC. Evidence level: ongoing Phase I/II; results pending.

Phase I/II · recruiting
Clinical trial Phase 1/2 Recruiting
HCQ Tunlametinib + pucotenlimab + HCQ in NRAS-mutant melanoma (NCT07750067) — recruiting
Summary

Recruiting Phase II combining MEK inhibitor tunlametinib, PD-1 antibody pucotenlimab, and hydroxychloroquine in metastatic NRAS-mutant melanoma. Evidence level: planned/ongoing Phase II; no results yet.

Phase II · recruiting
Clinical trial Phase 2 Recruiting
Fenbendazole Advanced Science (2026): fenbendazole nanoplatform + photothermal therapy induces ferroptosis in bladder cancer
Summary

Intravesical nanoformulation combining fenbendazole with photothermal therapy reported to trigger ferroptosis and dual immunotherapy signals in bladder cancer models. Evidence level: preclinical nanomedicine — not a registered human cancer trial of fenbendazole.

Nano + PTT · preclinical 2026
Lab study Preclinical
HCQ The Oncologist: Phase I results of binimetinib plus hydroxychloroquine in metastatic pancreatic cancer (NCT04132505)
Summary

Published results (Haldar et al., MD Anderson): 34 patients with KRAS-mutant metastatic pancreatic cancer who had already had at least one treatment got the MEK inhibitor binimetinib plus hydroxychloroquine. The starting dose was poorly tolerated (one grade 3 muscle-enzyme rise with kidney impairment, one grade 3 QT prolongation), so the dose was lowered to binimetinib 30 mg + HCQ 600 mg twice daily. Of 31 patients who could be assessed, 2 had a partial response and 9 had stable disease (response rate 6.5%, disease control 35.5%); median progression-free survival was 1.9 months and median overall survival 5.3 months. The authors conclude the combination had a challenging toxicity profile and limited activity. Honest negative early-phase result.

Phase I · n=34 · negative · 2026
Clinical trial Phase 1
HCQ HITMAN-PC: Phase I HCQ + suba-itraconazole in biochemically recurrent prostate cancer (NCT03513211)
Summary

Cancer Research Communications Phase I (n=11): MTD/RP2D HCQ 600 mg BID with suba-itraconazole 150 mg BID; common AEs hypertension, QTc prolongation, diarrhea, nausea; no PSA declines ≥50%; median PSA-PFS 5.5 months. Planned Phase II expansion not pursued (limited activity + changing BCR landscape).

Phase I published · negative/futile
Clinical trial Phase 1
Mebendazole Chem Biol Interact: mebendazole slowed gastric cancer cells in the lab by hitting nucleotide-building enzymes
Summary

Lab study (da Silva et al., Brazil): in gastric cancer cell lines, mebendazole reduced cell growth about as much as the chemotherapy drug 5-FU, with less toxicity to non-cancer cells. It lowered expression of nucleotide-metabolism genes (TYMS, MTHFD1, HPRT1, PRPS1), stopped cells in the G0/G1 phase, and computer docking suggested it binds PRPS1 and HPRT1. Patient tumor data linked higher levels of these genes to worse survival. Results are in lab cells and computer models only; not tested in people.

Lab study (cell lines) · 2026
Lab study Preclinical
HCQ J Immunother Cancer: REVOLUTION Phase 1 tested hydroxychloroquine with chemo and ipilimumab in metastatic pancreatic cancer (NCT04787991)
Summary

Phase 1 results (O'Reilly et al.) from REVOLUTION, an open-label, non-randomized platform trial in people with untreated metastatic pancreatic cancer. Everyone got gemcitabine, nab-paclitaxel and two doses of ipilimumab. Cohort A (15 people) also got nivolumab; cohort B (15 people) also got hydroxychloroquine 600 mg twice a day. In the HCQ cohort, 6 of 15 (40%) had tumor shrinkage and 12-month survival was 53.9%; the nivolumab cohort had 33% shrinkage and 65.5% 12-month survival. Serious (grade 3-4) treatment side effects hit 53% in the HCQ cohort, and one patient in that cohort died of a treatment-related event. HCQ was hard to tolerate, causing dose changes, missed doses and early stops, and blood tests showed it did block autophagy. The cohorts were small with no chemo-only comparison, and neither will be expanded.

Phase I · n=30 (15 per cohort) · non-randomized, no control · 2026
Clinical trial Phase 1 Completed
Ivermectin J Vet Intern Med: adding ivermectin to vincristine shortened treatment for a contagious tumor in dogs
Summary

Veterinary trial (Soltanali et al.): 20 pet dogs with canine transmissible venereal tumor were randomly assigned, double-blind, to standard weekly vincristine alone or vincristine plus two ivermectin injections (0.5 mg/kg). Dogs on the combination reached confirmed remission sooner, about 4.3 vs 5.9 weeks for aggressive tumors and 3.8 vs 5.5 weeks for less aggressive ones, with no added blood or kidney toxicity seen. Small study in dogs with a tumor type that responds well to chemotherapy; not tested in people.

Randomized veterinary trial (dogs) · n=20 · 2026
Animal study Preclinical
Fenbendazole RETRACTED: Fenbendazole 3-patient case series (Case Rep Oncol / Makis et al.)
Summary

The July 2025 Case Reports in Oncology 3-patient fenbendazole self-administration series (originally PMC12215191) was retracted ~Jan 21, 2026 for undisclosed conflict of interest — not for fabrication of outcomes. Do not cite the unretracted framing as supporting evidence. Retraction: PMC12823103; Karger statement: https://karger.com/cro/article/19/1/169/941881/Retraction-StatementPaper-by-William-Makis-Ilyes. Evidence level: retraction notice.

Retraction notice
Retraction
Fenbendazole World J Clin Cases: severe liver injury linked to self-dosed fenbendazole in a patient on immunotherapy
Summary

Case report (Krishnan et al.): a 47-year-old woman with metastatic colon cancer on nivolumab/relatlimab developed severe liver injury after raising her own fenbendazole dose. A standard causality score (RUCAM 8, probable) pointed to fenbendazole; her liver tests improved quickly after she stopped it, and immunotherapy was restarted safely without the injury coming back. A later published letter argued the pattern could reflect tumor cell death instead, and the authors replied defending their view. Single patient; cannot prove cause.

Case report (safety) · 2026
Case report
Ivermectin Drug Deliv Transl Res: platelet-coated ivermectin nanocrystals tested against triple-negative breast cancer in cells and mice
Summary

Preclinical study (Sheir et al., Egypt): researchers made ivermectin into nanocrystals to get around its poor solubility, then coated them with platelet membranes to help them reach tumors. In lab cells the coated version was more toxic to triple-negative breast cancer cells (MDA-MB-231) than the uncoated one and gentler on normal fibroblasts. In mice with breast tumors it gathered more in the tumor, slowed tumor growth and increased immune T-cell infiltration. Lab cells and mice only; not tested in people.

Lab + mouse study · 2026
Animal study Preclinical
HCQ Window-of-opportunity HCQ in resectable localized prostate cancer (NCT06408298) — recruiting
Summary

Randomized double-blind placebo-controlled early Phase I proof-of-principle study of oral hydroxychloroquine before prostatectomy, measuring autophagy markers (p62, LC3-II, NBR1) in tumor tissue (n≈20). Evidence level: biomarker-focused pilot; not an efficacy trial.

Early Phase I · recruiting
Clinical trial Early Phase 1 Recruiting
Methylene Blue Topical formulated methylene blue for inoperable cutaneous SCC (NCT07311057)
Summary

Small single-arm pilot (enrolling by invitation) of topical methylene blue dressing for advanced/inoperable squamous cell carcinoma not suitable for radiotherapy. Evidence level: tiny pilot; preliminary only.

Pilot · enrolling by invitation
Clinical trial Enrolling by invitation
HCQ AUTOMAIN: autophagy maintenance with HCQ in ovarian cancer (NCT06971744) — recruiting
Summary

Recruiting Phase II focused on autophagy maintenance strategies including hydroxychloroquine in ovarian cancer. Evidence level: ongoing Phase II; efficacy unknown.

Phase II · recruiting
Clinical trial Phase 2 Recruiting
Mebendazole PLoS One: mebendazole plus gefitinib cut lung and breast cancer cell growth in the lab
Summary

Lab study (El-Tanani et al.): in A549 lung cancer and MDA-MB-231 triple-negative breast cancer cells, gefitinib 1 µM plus mebendazole 0.5 µM reduced cell viability to about 8-10% and 15%, well below either drug alone. In the lung cells the combination lowered inflammatory cytokines (IL-1β, IL-6, TNF-α, IFN-γ) and changed genes tied to cell division and nuclear transport. Lab cells only; not tested in animals or people.

Lab study (cell lines) · 2025
Lab study Preclinical
Ivermectin BMC Pharmacol Toxicol (2025): ivermectin + doxorubicin synergy in oral squamous cell carcinoma (in vitro)
Summary

Laboratory investigation of ivermectin alone and with doxorubicin in OSCC models, reporting synergistic cytotoxicity signals. Evidence level: in vitro preclinical — not clinical trial data.

In vitro · 2025
Lab study Preclinical
HCQ Int J Mol Sci: hydroxychloroquine slowed gum (gingival) cancer cells more than tongue cancer cells in the lab
Summary

Lab study (Baroudi et al.): in oral squamous cell carcinoma cell lines, hydroxychloroquine clearly reduced growth and colony formation of gingival cancer cells (Ca9-22) but had only a moderate effect on tongue cancer cells (SCC-9); another tongue line and normal oral cells showed no response or only non-specific toxicity at high doses. The drug blocked autophagy and changed apoptosis, mitochondrial and DNA-damage markers. Lab cells only; not tested in people.

Lab study (cell lines) · 2025
Lab study Preclinical
Fenbendazole Neuro-Oncology abstract: fenbendazole, papain and sodium selenite showed activity against brain tumor cells in the lab; implantable scaffold in development
Summary

Conference abstract, lab study (Khagi et al., Society for Neuro-Oncology 2025 meeting, EXTH-110): researchers tested fenbendazole, papain (a papaya enzyme) and sodium selenite against several brain tumor cell lines and report significant antitumor activity for each and combined synergy in the dish. They are developing a biodegradable polyvinyl alcohol scaffold to release the three agents directly into the brain tumor surgery cavity. Conference abstract only, not a full peer-reviewed paper; the abstract gives no detailed numbers; in lab cells only; the scaffold was not reported as tested in animals or people.

Lab study (conference abstract, brain tumor cells) · 2025
Lab study Preclinical
HCQ J Mater Sci Mater Med: hydroxychloroquine boosted targeted doxorubicin nanoparticles against colorectal cancer cells in the lab
Summary

Lab study (Saffar et al.): researchers loaded the chemotherapy drug doxorubicin into folic-acid-tagged metal-organic framework nanoparticles (UiO-66-NH2-FA) that release more drug in acidic conditions. In HT-29 colorectal cancer cells the targeted particles were taken up more and killed more cells, and adding hydroxychloroquine (an autophagy blocker) increased the cell-killing effect compared with the particles alone. The authors say animal studies are still needed. Lab cells only; not tested in animals or people.

Lab study (cell lines) · 2025
Lab study Preclinical
Methylene Blue Topical formulated methylene blue for inoperable BCC subtypes (NCT07311070)
Summary

Pilot of topical methylene blue (0.5 mg/mL) every other day for one month in morpheaform, infiltrative, or noduloulcerative basal cell carcinoma not suitable for surgery/radiotherapy. Evidence level: small pilot; efficacy unproven.

Pilot · enrolling by invitation
Clinical trial Enrolling by invitation
HCQ Cancer Gene Ther: paricalcitol plus HCQ boosted 5-FU/oxaliplatin chemo against pancreatic cancer in cells and mice
Summary

Preclinical study (Bandi et al.): adding the vitamin D analog paricalcitol and hydroxychloroquine to 5-FU plus oxaliplatin increased cancer cell death in three pancreatic cancer cell lines. In mice the combination slowed tumor growth and activated T and NK immune cells. The authors link the effect to lower integrin beta-4 and other tumor-matrix proteins and say it should be tested in trials. Cells and mice only; not tested in people.

Lab + mouse study · 2025
Animal study Preclinical
Methylene Blue Intratumoral methylene blue + radiation for recurrent radiation-resistant HNSCC (NCT07435415)
Summary

Early Phase I pilot of local methylene blue injection as a potential radiosensitizer with concurrent radiation in locoregional recurrent head and neck squamous cell carcinoma (n≈10). Evidence level: small feasibility/safety pilot; efficacy unknown.

Early Phase I · active, not recruiting
Clinical trial Early Phase 1 Active, not recruiting
Fenbendazole Translational Lung Cancer Research (2025): fenbendazole + DADA synergy in A549 xenografts
Summary

Mouse study combining fenbendazole with diisopropylamine dichloroacetate (DADA); authors report synergistic tumor growth inhibition and call for clinical study. Evidence level: preclinical animal only.

Xenograft · 2025
Animal study Preclinical
Fenbendazole Frontiers Pharmacology (2025): fenbendazole induces pyroptosis in breast cancer cells
Summary

Preclinical study linking fenbendazole to pyroptosis via HK2/caspase-3/GSDME signaling in breast cancer cell models. Evidence level: preclinical in vitro — not human trial evidence.

In vitro · 2025
Lab study Preclinical
Ivermectin Current Oncology Reports (2025): ivermectin in cancer — caution vs exploration
Summary

Peer-reviewed review summarizing limited human clinical evidence for ivermectin as cancer therapy, noting widespread off-label interest and the need for well-designed trials. Evidence level: narrative review; not new clinical efficacy data.

Narrative review 2025
Review
HCQ Phase III: endocrine therapy ± high-dose palbociclib and hydroxychloroquine in HR+/HER2− advanced breast cancer (NCT07061717) [Pending]
Summary

Large randomized Phase III trial (estimated n≈474) comparing standard palbociclib + endocrine therapy versus arms adding hydroxychloroquine (with standard- or high-dose palbociclib). Evidence level: confirmatory-design trial planned; no results yet.

Phase III · not yet recruiting
Clinical trial Phase 3 Not yet recruiting
Methylene Blue Adjunctive methylene blue for immunotherapy-related CRS and ICANS (NCT07169487) — recruiting
Summary

Phase I dose-escalation study of IV methylene blue for cytokine release syndrome (CRS) or ICANS after CAR-T or bispecific antibodies. Evidence level: early Phase I safety/preliminary efficacy; not an approved cancer treatment indication.

Phase I · recruiting
Clinical trial Phase 1 Recruiting
Mebendazole Neuro-Oncology Practice: Phase 1 mebendazole monotherapy in refractory pediatric brain tumors (NCT02644291)
Summary

Peer-reviewed Phase 1 (n=17; Johns Hopkins / All Children’s): oral mebendazole up to 2500 mg/m²/day was tolerable with no dose-limiting toxicities; mean PFS 7.6 weeks (range 2–24). Authors conclude limited evidence of single-agent efficacy in refractory/progressive pediatric brain tumors. Complements the existing registry listing for NCT02644291.

Phase I published · limited efficacy
Clinical trial Phase 1
IvermectinFenbendazole ASCO: oncologists urged to discuss ivermectin and fenbendazole proactively
Summary

ASCO policy/news item summarizing clinical guidance that ivermectin and fenbendazole should not be recommended for cancer treatment outside well-designed clinical trials, and advising routine conversations about supplements. Evidence level: professional society guidance — not a trial result.

Society guidance
Other
Ivermectin ASCO 2025 abstract: early safety signals for ivermectin + balstilimab in metastatic TNBC
Summary

ASCO abstract (meeting ID 250156 / JCO e13146): combination described as safe/well tolerated in early accrual; among 8 evaluable patients, 1 PR, 1 SD, 6 PD (median PFS 2.5 months; 4-month clinical benefit rate 37.5%). Evidence level: conference abstract, small n, preliminary — not peer-reviewed full results.

Conference abstract · preliminary
Other
Fenbendazole Molecules (2025): fenbendazole antitumor activity in cervical cancer models (cells + stem cells)
Summary

Study reporting fenbendazole activity against cervical cancer cells and cancer stem cell–like populations in preclinical models. Evidence level: preclinical — not approved human cancer therapy.

In vitro · 2025
Lab study Preclinical
Mebendazole Neuro-Oncology Advances (2025): mebendazole + radiation in IDH-mutant glioma models
Summary

Preclinical work exploring mebendazole combined with radiation therapy in an IDH-mutant glioma context. Evidence level: preclinical — not human efficacy data.

Preclinical · RT combination 2025
Lab study Preclinical
HCQ HCQ + methotrexate/capecitabine/bevacizumab vs regorafenib in RAS-mutant refractory mCRC (NCT06949982)
Summary

Recruiting Phase II comparing a hydroxychloroquine-containing multi-drug regimen versus regorafenib in refractory RAS-mutant metastatic colorectal cancer. Evidence level: ongoing comparative Phase II; no results yet.

Phase II · recruiting
Clinical trial Phase 2 Recruiting
HCQ Discover Oncology: HCQ + chemo in platinum-sensitive relapsed ovarian cancer — Phase II negative
Summary

Randomized Phase II (n=59) adding hydroxychloroquine 200 mg BID to carboplatin-based chemotherapy in platinum-sensitive relapsed ovarian cancer. No benefit on ORR (85% vs 80%), PFS (12 vs 11 months), or OS (16 vs 21 months) versus chemo alone; HCQ was well tolerated. Honest negative RCT; pairs with ongoing AUTOMAIN. Evidence level: randomized Phase II — negative primary endpoint. Also PMC11839959.

Phase II RCT · negative
Clinical trial Phase 2
HCQ npj Breast Cancer: Phase I HCQ with continuous low-dose palbociclib + letrozole (NCT03774472)
Summary

Open-access Phase I report: HCQ was tolerable; RP2D 800 mg/day with continuous palbociclib 75 mg/day + letrozole; best responses included 2 partial responses and 11 stable disease among 14 evaluable patients. Evidence level: single-arm Phase I; larger randomized studies needed.

Phase I published · peer-reviewed
Review
Fenbendazole BMC Cancer (2024): fenbendazole transcriptome study in ovarian cancer models
Summary

In vitro and xenograft mouse work reporting proliferation inhibition, apoptosis/mitotic catastrophe signals, and oral fenbendazole effects on tumor growth in ovarian cancer models. Evidence level: preclinical — not a human trial.

In vitro + xenograft 2024
Animal study Preclinical
HCQ Med (Cell Press): HCQ + high-dose palbociclib after CDK4/6i failure (NCT05953350)
Summary

Phase Ib/II in 29 HR+/HER2− patients after first-line palbociclib failure. RP2D: HCQ 600 mg BID + palbociclib 200 mg daily. Reported ORR 41.4% in all enrolled; grade ≥3 neutropenia/leukopenia ~25%. Evidence level: single-arm Phase Ib/II; needs randomized confirmation.

Phase Ib/II published
Clinical trial Phase 1/2
HCQ HCQ for radiation-induced oral mucositis (NCT06939582) — recruiting
Summary

Recruiting Phase I/II randomized study of hydroxychloroquine sulfate tablets versus placebo for prevention/treatment of radiation-induced oral mucositis and dysgeusia (n≈158). Supportive-care indication, not antitumor efficacy. Evidence level: ongoing supportive-care trial.

Phase I/II · recruiting · supportive care
Clinical trial Phase 1/2 Recruiting
Fenbendazole Anticancer Research (2024): oral fenbendazole for cancer therapy — review
Summary

Review of preclinical anticancer activity, oral pharmacokinetics, and toxicity; emphasizes fenbendazole is not FDA/EMA-approved for human cancer and that clinical trials are needed. Evidence level: narrative review.

Review 2024
Review
HCQ Pretreatment HCQ before radiotherapy and chemotherapy in advanced NPC (NCT06389201)
Summary

Recruiting study evaluating hydroxychloroquine pretreatment before radiotherapy and chemotherapy in advanced nasopharyngeal carcinoma. Evidence level: early interventional; not standard of care.

Interventional · recruiting
Clinical trial Recruiting
HCQ HCQ + palbociclib/letrozole neoadjuvant ER+/HER2− breast cancer (NCT03774472) — completed
Summary

MD Anderson Phase I/II of autophagy inhibition with HCQ added to continuous low-dose palbociclib + letrozole. Completed; Phase I results published in npj Breast Cancer (see companion news entry). Evidence level: early-phase completed trial.

Phase I/II · completed
Clinical trial Phase 1/2 Completed
HCQ LY3214996 ± HCQ in metastatic pancreatic cancer (NCT04386057) — completed
Summary

Completed Dana-Farber Phase II of ERK inhibitor LY3214996 alone or with hydroxychloroquine in advanced pancreatic cancer. Evidence level: completed Phase II; review registry/publications for outcomes before drawing conclusions.

Phase II · completed
Clinical trial Phase 2 Completed
Ivermectin Cedars-Sinai trial listing: ivermectin and balstilimab in metastatic TNBC Older
Summary

Institutional patient-facing summary of the recruiting Phase I/II study pairing oral ivermectin with investigational anti–PD-1 balstilimab (NCT05318469). Notes experimental use in this setting. Evidence level: trial information page, not outcome data.

Institutional trial page
Other
Ivermectin Ivermectin + balstilimab/pembrolizumab in metastatic TNBC (NCT05318469) — recruiting Older
Summary

Cedars-Sinai Phase I/II study of oral ivermectin with immune checkpoint inhibitors in metastatic triple-negative breast cancer. Estimated primary completion Oct 2026. Evidence level: ongoing interventional trial; efficacy not established.

Phase I/II · recruiting
Clinical trial Phase 1/2 Recruiting
HCQ MEK inhibitor + HCQ ± bevacizumab for refractory RAS-mutant cancers (NCT06229340) — status unknown Older
Summary

Phase II study comparing leflunomide versus MEK inhibitor plus hydroxychloroquine (± bevacizumab) in refractory RAS-mutant colorectal, pancreas, or lung cancer (n≈20). Evidence level: small ongoing Phase II; interpret cautiously. Registry update: ClinicalTrials.gov now lists this trial's status as unknown (last known: recruiting; not updated since Jan 2024).

Phase II · status unknown
Clinical trial Phase 2 Unknown status
HCQ HCQ with FOLFIRI + bevacizumab in DTP-high metastatic colorectal cancer (NCT05843188) Older
Summary

Phase II study of hydroxychloroquine added to FOLFIRI and bevacizumab in metastatic colorectal cancer enriched for drug-tolerant persister (DTP) biology. Status: active, not recruiting. Evidence level: ongoing Phase II.

Phase II · active, not recruiting
Clinical trial Phase 2 Active, not recruiting
HCQ Phase Ib/II: HCQ + high-dose palbociclib after CDK4/6i failure (NCT05953350) Older
Summary

Registry record for the Gong et al. Phase Ib/II combination of hydroxychloroquine with escalated palbociclib doses in advanced HR+/HER2− disease after CDK4/6 inhibitor failure. Evidence level: see published Med paper for outcomes.

Phase Ib/II · registry
Clinical trial Phase 1/2 See publication
Methylene Blue Phase III: methylene blue mouthwash for oral mucositis pain in cancer (NCT05878405) — completed Older
Summary

Mayo Clinic Phase III comparing methylene blue oral rinse versus standard-of-care mouthwash for oral mucositis pain in patients with solid or hematologic malignancies (n≈49). Supportive-care pain indication. Evidence level: completed Phase III supportive-care trial; not an antitumor study.

Phase III · completed · supportive care
Clinical trial Phase 3 Completed
Fenbendazole J Gynecol Oncol: fenbendazole-PLGA nanoparticles in ovarian cancer models Older
Summary

Preclinical work improving fenbendazole solubility via PLGA nanoparticles; intravenous nanoparticles reduced tumor weight in cell-line and patient-derived xenografts where oral fenbendazole did not. Evidence level: preclinical formulation study.

Nanoparticle · xenograft
Animal study Preclinical
HCQ Devimistat (CPI-613) + HCQ with 5-FU or gemcitabine in chemorefractory solid tumors (NCT05733000) — recruiting Older
Summary

Northwestern Phase II of mitochondrial metabolism inhibitor CPI-613 (devimistat) plus hydroxychloroquine with 5-fluorouracil or gemcitabine in advanced chemorefractory solid tumors including biliary, colorectal, GEJ, and lung adenocarcinoma (n≈94). Evidence level: ongoing Phase II; efficacy not established.

Phase II · recruiting
Clinical trial Phase 2 Recruiting
Ivermectin [Older] Frontiers Oncology: ivermectin, NETs, and melanoma metastasis (mouse) Older
Summary

Mouse study reporting that ivermectin reduced lung metastasis associated with neutrophil extracellular traps without reducing primary tumor growth. Evidence level: preclinical animal study — not human trial data.

Mouse model · older
Animal study Preclinical
Methylene Blue [Older] MB-PDT effects on oral carcinoma and leukoplakia cells (PMC) Older
Summary

Laboratory study of methylene blue photodynamic therapy reducing cell viability and MMP-9 in oral carcinoma and leukoplakia cell models. Evidence level: in vitro preclinical.

In vitro PDT · older
Lab study Preclinical
Mebendazole Phase I mebendazole for recurrent/progressive pediatric brain tumors (NCT02644291) — completed Older
Summary

Completed Johns Hopkins Phase I safety study of mebendazole in children/young adults with recurrent medulloblastoma or high-grade glioma / DIPG. Evidence level: completed Phase I; registry results should be reviewed separately.

Phase I · completed
Clinical trial Phase 1 Completed
Mebendazole [Older] Life Sciences (2022): mebendazole + FOLFOX4/bevacizumab in mCRC (NCT03925662) Older
Summary

Randomized double-blind placebo-controlled report (n=40) claiming higher overall response (65% vs 10%) and longer PFS (9.25 vs 3 months) with mebendazole 500 mg BID added to bevacizumab/FOLFOX4. Evidence level: small single-center RCT; needs independent replication before practice change.

Small RCT · older · needs replication
Clinical trial
HCQ COAST: multi-drug oral regimen including HCQ in solid tumors/prostate cancer (NCT05036226) — recruiting Older
Summary

Medical University of South Carolina Phase I/II testing oral combinations of hydroxychloroquine with metformin, sirolimus, and optionally dasatinib/nelfinavir in advanced solid tumors and recurrent prostate cancer (n≈76). Evidence level: ongoing multi-drug early-phase study; efficacy unknown.

Phase I/II · recruiting
Clinical trial Phase 1/2 Recruiting
HCQ HCQ + chlorphenesin carbamate with mFOLFIRINOX in pancreatic cancer (NCT05083780) Older
Summary

Phase I combination of hydroxychloroquine and chlorphenesin carbamate with mFOLFIRINOX in pancreatic cancer. Status: active, not recruiting. Evidence level: early Phase I safety study.

Phase I · active, not recruiting
Clinical trial Phase 1 Active, not recruiting
HCQ ABBY: abemaciclib ± hydroxychloroquine for MRD in breast cancer (NCT04523857) — recruiting Older
Summary

Phase II University of Pennsylvania trial testing abemaciclib alone vs abemaciclib + HCQ to target disseminated tumor cells / minimal residual disease after primary breast cancer therapy. Evidence level: ongoing randomized Phase II; results pending.

Phase II · recruiting
Clinical trial Phase 2 Recruiting
HCQ PHL stroma-modifying regimen (paricalcitol + HCQ + losartan) in pancreatic cancer (NCT05365893) Older
Summary

Fox Chase early Phase I neoadjuvant study of paricalcitol, hydroxychloroquine, and losartan (PHL) to modify stroma in resectable pancreatic ductal adenocarcinoma (n≈20). Status: active, not recruiting. Evidence level: small early-phase stroma-focused study.

Early Phase I · active, not recruiting
Clinical trial Early Phase 1 Active, not recruiting
Ivermectin [Older] Frontiers: ivermectin inhibits colorectal cancer cell growth (preclinical) Older
Summary

In vitro study reporting dose-dependent growth inhibition, ROS-mediated mitochondrial apoptosis, and S-phase arrest in colorectal cancer cell lines. Evidence level: preclinical cell work only — not human clinical efficacy.

In vitro · older
Lab study Preclinical
HCQ Avelumab or HCQ ± palbociclib to eliminate dormant breast cancer (NCT04841148) — active, not recruiting Older
Summary

Phase II multi-arm study exploring avelumab or hydroxychloroquine with or without palbociclib to clear dormant breast cancer cells. Evidence level: ongoing interventional; efficacy not established.

Phase II · active, not recruiting
Clinical trial Phase 2 Active, not recruiting
MebendazoleFenbendazole Mebendazole + temozolomide in newly diagnosed high-grade glioma (NCT01729260) — completed Older
Summary

Completed Johns Hopkins Phase I dose-finding study of mebendazole with temozolomide after chemoradiation. Protocol notes preclinical fenbendazole observations led investigators to select mebendazole for human testing. Evidence level: completed Phase I; not proof of clinical benefit.

Phase I · completed
Clinical trial Phase 1 Completed
HCQ Binimetinib + HCQ in advanced KRAS-mutant NSCLC (NCT04735068) — completed Older
Summary

Penn Phase II of MEK inhibitor binimetinib plus hydroxychloroquine in advanced KRAS-mutant non-small cell lung cancer (n=9 enrolled). Evidence level: completed small Phase II; review registry/publications before drawing conclusions.

Phase II · completed · small n
Clinical trial Phase 2 Completed
Fenbendazole [Older] Chiang et al.: fenbendazole enhancing anti-tumor effect — case series Older
Summary

Small uncontrolled case series (often cited as Stanford/Chiang) describing radiographic responses in genitourinary cancer patients who took fenbendazole with concurrent or recent standard therapies. Evidence level: anecdotal; concurrent treatments confound attribution.

Case series · older
Case report
HCQ Nab-paclitaxel + gemcitabine + cisplatin + HCQ in non-metastatic pancreas cancer (NCT04669197) — completed Older
Summary

HonorHealth Phase II neoadjuvant study adding hydroxychloroquine to nab-paclitaxel, gemcitabine, and cisplatin in untreated resectable, borderline, or locally advanced pancreatic adenocarcinoma (n≈19), focusing on CA19-9 normalization. Evidence level: completed small Phase II.

Phase II · completed
Clinical trial Phase 2 Completed
HCQ Nivolumab ± ipilimumab + hydroxychloroquine in advanced melanoma (NCT04464759) Older
Summary

Phase I/II of checkpoint blockade plus HCQ in advanced melanoma. Status: active, not recruiting. Evidence level: early-phase combination; await published outcomes.

Phase I/II · active, not recruiting
Clinical trial Phase 1/2 Active, not recruiting
HCQ Paricalcitol + HCQ with gemcitabine/nab-paclitaxel in advanced pancreatic cancer (NCT04524702) — completed Older
Summary

Emory Phase II of vitamin D analog paricalcitol and hydroxychloroquine combined with gemcitabine and nab-paclitaxel in advanced/metastatic pancreatic adenocarcinoma (n≈10). Evidence level: completed small Phase II.

Phase II · completed · small n
Clinical trial Phase 2 Completed
HCQ [Older] Neoadjuvant gemcitabine/nab-paclitaxel ± high-dose HCQ in pancreatic cancer (NCT01978184) Older
Summary

Randomized Phase II preoperative study: HCQ arm improved pathologic and CA19-9 responses but did not improve overall or recurrence-free survival. Evidence level: randomized Phase II — mixed endpoints; no survival benefit shown.

Randomized Phase II · older · mixed
Clinical trial Phase 2
HCQ Ulixertinib (ERK inhibitor) + HCQ in MAPK-mutated GI adenocarcinomas (NCT04145297) — completed Older
Summary

Utah Phase I dose-escalation of ERK inhibitor ulixertinib (BVD-523) with fixed-dose hydroxychloroquine in advanced MAPK-mutated gastrointestinal adenocarcinomas (n≈16). Evidence level: completed Phase I; early safety/dose data only.

Phase I · completed
Clinical trial Phase 1 Completed
HCQ PBTC: dabrafenib/trametinib + HCQ in recurrent BRAF-aberrant glioma (NCT04201457) Older
Summary

Pediatric Brain Tumor Consortium Phase I/II adding hydroxychloroquine to dabrafenib and/or trametinib in children with recurrent/progressive low- or high-grade glioma with BRAF aberration (n≈57). Status: active, not recruiting. Evidence level: ongoing early-phase pediatric combination; efficacy not established.

Phase I/II · active, not recruiting
Clinical trial Phase 1/2 Active, not recruiting
HCQ Carfilzomib + HCQ in relapsed/refractory multiple myeloma (NCT04163107) — completed Older
Summary

Norwegian Phase I of proteasome inhibitor carfilzomib plus hydroxychloroquine (with dexamethasone) in relapsed/refractory multiple myeloma (n≈19). Evidence level: completed Phase I; check publications for outcomes.

Phase I · completed
Clinical trial Phase 1 Completed
HCQ Binimetinib + HCQ in KRAS-mutant metastatic pancreatic cancer (NCT04132505) — completed Older
Summary

MD Anderson Phase I of binimetinib plus hydroxychloroquine in KRAS-mutant metastatic pancreatic adenocarcinoma (n≈34). Evidence level: completed Phase I dose-finding; not proof of clinical benefit.

Phase I · completed
Clinical trial Phase 1 Completed
HCQ [Older] JAMA Oncology: gemcitabine/nab-paclitaxel ± HCQ in advanced pancreatic cancer Older
Summary

Phase 2 randomized clinical trial in metastatic/advanced pancreatic cancer: higher response rate with HCQ but no overall survival benefit. Evidence level: randomized Phase II — response ≠ survival benefit.

Randomized Phase II · older
Clinical trial Phase 2
Mebendazole Mebendazole as adjuvant treatment for colon cancer (NCT03925662) — recruiting Older
Summary

Tanta University Phase III–labeled randomized study of mebendazole added to FOLFOX + bevacizumab in colorectal cancer. Evidence level: registry lists recruiting; interpret published companion results cautiously and independently.

Phase III · recruiting
Clinical trial Phase 3 Recruiting
HCQ Gemcitabine + docetaxel + HCQ in recurrent/refractory osteosarcoma (NCT03598595) Older
Summary

MD Anderson Phase I/II of hydroxychloroquine with gemcitabine and docetaxel in recurrent or refractory osteosarcoma (n≈31). Status: active, not recruiting. Evidence level: early-phase sarcoma combination; await published outcomes.

Phase I/II · active, not recruiting
Clinical trial Phase 1/2 Active, not recruiting
Mebendazole RepoMeb: mebendazole in advanced GI cancer or CUP (NCT03628079) — terminated Older
Summary

Phase 2a TDM-guided study of mebendazole in advanced gastrointestinal cancer or cancer of unknown origin. Terminated for lack of effect (n=11). Evidence level: small terminated early-phase study — negative signal in this setting.

Phase 2a · terminated (no effect)
Clinical trial Phase 2 Terminated
HCQ CLEVER pilot: HCQ, everolimus, or both to prevent recurrent breast cancer (NCT03032406) Older
Summary

Phase II pilot of hydroxychloroquine, everolimus, or the combination for prevention of recurrent breast cancer (stage IIB+). Status: active, not recruiting. Evidence level: prevention-focused early Phase II.

Phase II · active, not recruiting
Clinical trial Phase 2 Active, not recruiting
HCQ LIMIT: dabrafenib + trametinib + HCQ in advanced BRAF-mutant melanoma (NCT02257424) — completed Older
Summary

Penn Phase I/II of hydroxychloroquine added to dabrafenib and trametinib in advanced BRAF-mutant melanoma (n≈50). Companion imaging study NCT05279027 exists. Evidence level: completed early-phase combination; review publications for final outcomes.

Phase I/II · completed
Clinical trial Phase 1/2 Completed
HCQ [Older] HCQ monotherapy in previously treated metastatic pancreatic cancer (NCT01273805) Older
Summary

Completed early study of hydroxychloroquine alone in heavily pretreated metastatic pancreatic cancer; short median PFS/OS reported historically. Evidence level: older single-agent study — limited activity as monotherapy.

Early · completed · older
Clinical trial Completed
Mebendazole Mebendazole with standard chemo for pediatric gliomas (NCT01837862) Older
Summary

Phase I/II Northwell/Cohen Children's study of oral mebendazole plus standard regimens in pediatric low- and high-grade gliomas / DIPG. Status: active, not recruiting. Evidence level: early-phase combination safety/efficacy study.

Phase I/II · active, not recruiting
Clinical trial Phase 1/2 Active, not recruiting
HCQ Erlotinib ± hydroxychloroquine in EGFR-mutant chemo-naive NSCLC (NCT00977470) Older
Summary

Phase II of erlotinib with or without HCQ in chemo-naive advanced NSCLC with EGFR mutations. Status listed active, not recruiting on registry scans. Evidence level: older Phase II combination; check current publications for final outcomes.

Phase II · older
Clinical trial Phase 2 Active, not recruiting

Reminder: Links and summaries are for exploration only. They do not imply safety, efficacy, or endorsement. Prefer peer-reviewed full papers and ClinicalTrials.gov records over headlines. Do your own due diligence and speak with a healthcare provider.

Edited Nov 12, 2026